Q4 2023 KKR Real Estate Finance Trust Inc Earnings Call

Participants

Jack Switala; IR Contact Officer; KKR Real Estate Finance Trust Inc

Matt Salem; CEO, Director; KKR Real Estate Finance Trust Inc

Patrick Mattson; President & COO; KKR Real Estate Finance Trust Inc

Sarah Barcomb; Analyst; BTIG, LLC

Don Fandetti; Analyst; Wells Fargo Securities

Stephen Laws; Analyst; Raymond James & Associates, Inc.

Jade Rahmani; Analyst; Keefe, Bruyette, & Woods, Inc.

Rick Shane; Analyst; JPMorgan Chase & Co

Kelly Wang; Analyst; Citi

Presentation

Operator

Good morning, and welcome to the KKR Real Estate Finance Trust fourth quarter 2023 financial results conference call.
(Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to Jack Switala. Please go ahead.
Great.

Jack Switala

Thanks, operator, and welcome to the KKR Real Estate Finance Trust earnings call for the fourth-quarter of 2023. As the operator mentioned, this is Jack Switala. Today, I'm joined on the call by our CEO, Matt Salem; our President and COO, Patrick Mattson; and our CFO, Kendra Decious.
I'd like to remind everyone that we will refer to certain non-GAAP financial measures on the call, which are reconciled to GAAP figures in our earnings release and in the supplementary presentation, both of which are available on the Investor Relations portion of our website. This call will also contain certain forward looking statements which do not guarantee future events or performance. Please refer to our most recently filed 10 K for cautionary factors related to these statements.
Before I turn the call over to Matt, I provide a brief recap of our results. For the fourth quarter of 2023, we reported a GAAP net loss of $18.7 million or negative $0.27 per share. Distributable earnings this quarter were negative $26 million or negative $0.37 per share, including a write off of $59 million or $0.85 per share.
Distributable earnings prior to realized losses were $0.47 per share relative to our Q4 $0.43 per share dividend. Book value per share as of December 31, 2023, was $15.52, a decline of approximately 5% quarter over quarter. Our CECL allowance decreased to $3.6 per share from $3.21 per share last quarter. In mid-January, we paid a cash dividend of $0.43 per common share with respect to the fourth quarter. Additionally, the Company's Board of Directors declared a dividend of $0.25 per share of common stock, with respect to the first quarter of 2024. The dividend is payable on April 15, 2024, to Keyera's common stockholders of record as of March 28, 2024.
With that, I'd now like to turn the call over to Matt.

Matt Salem

Thank you, Jack. Good morning, everyone, and thank you for joining us today. Before turning to the current market environment, company results and dividend commentary, I'd like to highlight key rest achievements. During 2023, we have focused our efforts on maintaining high levels of liquidity, fortifying our liability structure and proactively managing our portfolio, all of which has been critical to Keyera's ability to navigate this challenging market.
To be specific, we have built and maintained a market-leading liquidity position with the help of KKR Capital Markets with current cash on hand and undrawn corporate revolver capacity of nearly $600 million. Our financing continues to be best in class, which we further optimized by upsizing our repurchase agreement by $160 million and extending the term. KREF has no corporate debt or final facility maturities for two years.
76% of our secured financing as of year end was completely nonmark-to-market and the remaining 24% is only marked to credit. We received $767 million of repayments with office loans representing approximately 25% of total repayments. Our unfunded commitments as a percentage of the portfolio are 10% at year end 2023, down from 16% at year end 2022.
More than half of our portfolio is supported by multifamily and industrial properties. Multifamily remains our largest property type, representing approximately 41% of the portfolio. And we continue to see stable underlying performance across that segment, with weighted average rent increases of 3.9% year over year in our portfolio.
Office represents our second largest property type and since the beginning of last year has decreased as a percent of the portfolio from 26% to 22% today, including a full payoff last month of $173 million previously risk-rated four loans secured by a Washington DC property. Access to KKR's broader real estate platform with approximately 150 dedicated professionals and over $68 billion of assets under management has been instrumental in the management of K-Bro's portfolio.
Our capabilities have been further bolstered by our affiliated rated special servicer case Star with a team of more than 45 professionals and over $45 billion of special servicing rights, providing us with extensive expertise and access to sizable real-time market information.
We have been actively using the many tools at our disposal to execute on a variety of workout options, including modifications, restructurings, as well as taking title and managing real estate. Since our last call, the Federal Reserve has indicated an end to their interest rate hikes with potential rate cuts beginning in the first half of the year. Market sentiment has improved dramatically as some of the tail risk driven by inflation and higher interest rates has subsided, broader rally in equities and fixed income as impacting the commercial real estate equity and debt markets as well with significant tightening in CMBS and loan spreads over the past few months, the fear greed factor has clearly shifted and capital is flowing into the markets. We expect acquisition and refinance activity to increase this year, and we are seeing that in our own lending pipeline across our different capital sources. However, despite the strong momentum challenges remain given the value declines from the post-COVID interest rate environment. Today's higher interest rates and carrying costs combined with interest rate cap costs and near term maturity dates continue to stress real estate capital structures.
And now I'll discuss KREF's earnings, power and dividend philosophy as we get into 2024. Last year, KREF's earnings potential benefited from a higher interest rate environment with average run rate distributable earnings before losses of $0.48 per quarter throughout 2023. We stated last quarter that as we determine the run rate earnings potential of the business into 2024. The main drivers will be interest rates, portfolio performance and the ability to unlock equity held in our risk rated five assets. We have been proactive and transparent as we work through this market, and we have implemented a variety of strategies to optimize the outcome of our watchlist loans. Today, we have a few assets with the best path forward to maximize value would be to take title, operate the real estate and stabilize cash flows before selling each of different circumstances. But this is high-quality real estate that we have full confidence, we'll lease and stabilize over time. To put it simply, we have great real estate. We have ample liquidity and we have the resources and expertise to create value. Once stabilized, we believe we can sell the real estate at a higher value than our current mark. We recycle that capital into cash flowing assets and return to a more normal level of operating earnings.
However, getting to stabilization will require time and impact earnings in the interim to that end, Board of Directors declared a dividend of $0.25 per share for the first quarter. The dividend is set at a level where we can cover with distributable earnings ex losses with our performing loan portfolio under a number of different scenarios, including lower interest rates and the potential migration of loans to cost recovery and REO. To be clear, in the near term, we expect DEX. losses to be significantly higher than our dividend. Similar to how we've operated in the past, we are taking a proactive approach and making this adjustment now as opposed to waiting for our typical March declaration date in order to provide transparency.
Importantly, as we sell our REO portfolio, we can reinvest the capital into new loan assets to unlock additional earnings potential to put some context around this, we believe we can generate an additional $0.12 per share in distributable earnings per quarter. And this is just on our existing basis. Of course, the goal is to gain more than that over time. The assets driving this impact include our Portland retail and redevelopment property, our Philadelphia REO and Mountain View, projected REO and potentially the Seattle life science loan, which combined represent approximately $150 million of equity.
Continuing with our transparent reporting. We've added a new page in our earnings presentation, highlighting these assets with that I'll turn the call over to Patrick.

Patrick Mattson

Thank you, Matt. Good morning, everyone. I'll begin with updates to our CECL allowance and watch list. We finished the quarter with $213 million in CECL reserves, over two-thirds of which is held against the three five rated loans. Reserves decreased by $9 million quarter over quarter, primarily as a result of a few changes in Q4.
First, upon taking title to the five rated Philadelphia office asset, we realized a $59 million loss, which is lower than the $69 million asset-specific CECL reserve in the prior quarter. The seasonal amount was reversed and realized loss flowed through our distributable earnings in Q4.
Looking ahead, we are in discussions to sell two of the four properties in the near term and do not expect any impact to DE. as a result of the sale.
Second, we increased reserves on our loan secured by the Class A. office campus in Mountain View, California, reflecting a lower valuation. Given the continued slow leasing environment in Silicon Valley and the lower levels of liquidity, we expect to take title to the asset in the second quarter. Third, we downgraded the risk rating and increase reserves on a loan backed by a Class A. Seattle life sciences property. This property was built in 2021 and our sponsors purchased and converted the asset to life science lab use for spec lease-up.
As Matt mentioned, our multifamily portfolio has generally been stable with low single digit rental increases supporting NOI. growth. Both sponsors have renewed interest rate caps at maturities. However, we downgraded two multifamily loans to risk ratings of four in the quarter given ongoing discussions regarding interest rate caps, both properties are over 90% occupied and the loans are current on interest payments as we continue to work through our watchlist portfolio.
We saw positive outcomes on two of our Washington DC office loans that had been on the watch list last quarter. First, in January, the $173 million Washington DC office loan paid off in full as the sponsor completed a refinance with a new lender. This recently renovated and well-located Class A office asset had leased up to nearly 90% following the completion of the sponsor's CapEx plan. Our other watch list, Washington D.C. office loan is now risk-rated three, following a modification finalized in the fourth quarter, which included a $20 million principal paydown. The Class A property is 92% leased after positive momentum throughout last year.
With these positive outcomes, we have only one remaining risk-rated four office loan with current asset exposure in the form of a $37.5 million mezzanine loan secured by a Class A. property located in Boston post quarter end we entered into discussions with the sponsor and have begun modification negotiations, which may result in increased CECL reserves. And we expect to provide a further update on the status of the modification next quarter. In the past 13 months, PBF has received over $1 billion of repayments, including two full repayments totaling approximately $325 million we received in January. Both loans were previously risk-rated four, including the DC office loan previously mentioned and the New York City condo loan.
The weighted average risk rating on the portfolio remains 3.2 and 87% of our portfolio is risk rated three or better. Payback has built a diversified liability structure with $8.9 billion of financing capacity and $2.8 billion of undrawn capacity. Our non-mark-to-market capacity rate remains substantial at 76% and is diversified across two CRE CLOs and a number of match term lending agreements and asset-specific financing structures as well as our corporate revolver. Excluding match term secured financing, there are no corporate debt or final facility maturities until 2026.
KREF is well capitalized with $136 million of cash and $450 million of corporate revolver capacity available as of year end. Our best-in-class non-mark-to-market financing and high levels of liquidity coupled with our deep relationships with both our financing partners and borrowers. Physicians Care up strongly for this dynamic credit, an interest rate environment. Thank you for joining us today.
Now we're happy to take your questions.

Question and Answer Session

Operator

(Operator Instructions) Sarah Barcomb, BTIG.

Sarah Barcomb

Hey, good morning, everyone. And so I think a good place to start would be with this dividend cut, obviously a big reset here, and you mentioned in your prepared remarks that it was mostly the earnings drag from REO assets and non-performing loans that really drove this decision to cut. And I'm also wondering how much of the dividend type can be attributed to the near term risk of multifamily loan maturities that are coming up this year. We saw a couple of multifamily assets come on the watch list that's print on. You spoke to those dynamics in your prepared remarks, but we've talked a lot about this risk in recent quarters on these 2021, vintage loans still have so for TAP, well below today's levels and a significant portion of those caps should come off this year. So when you were thinking about this dividend reset, how much did that dynamic come into play on just thinking about multifamily debt service coverage and maybe the risk of seeing more sponsors pushback on re-upping that, that rate cap. I was hoping you could speak to that a little bit.

Matt Salem

Hey, Sarah. It's Matt. you have to take it and thank you for the question. I guess when we think about the multifamily portfolio, I think our view has changed that much from what we're what we saw what we spoke about last quarter, as you highlight, obviously, leverage has come up in those in those loans, just given the change in cap rates and the interest rate environment. Keep in mind, our portfolio is almost all Class A. and Class A. multifamily is pretty high-quality, pretty high-quality real estate we've got I think we've always been pretty transparent in terms of just how we're identifying our risk ratings and on those particular loans that you mentioned that moved into the four rated bucket this quarter, and we're obviously in modification discussions, both loans are current. So we'll kind of see where we ultimately end up there. But it comes back, I think, to our high-level view, which is there's going to be probably noise in the multi-family sector just given that change in value, but it really comes back to value at the end of the day when we think about projecting what's going to happen our multifamily portfolio, we're not expecting a lot of losses at all. I think there's in most cases, we'll be able to work with our borrowers where you're seeing the most stresses and borrowers that have a little bit less liquidity and so that interest-rate cap becomes more problematic.
The one thing I would highlight as well in the multifamily sector is the amount of liquidity there is tremendous. And when you think about the macro environment where we are today with a better understanding of interest rates, inflation, et cetera, and we've seen a pretty strong demand for multifamily assets as we look across both our equity and our and our credit business. So long-winded answer to your question, but we're not really anticipating that much trouble within the within the multifamily portfolio, but there will be a little bit of noise in there.

Sarah Barcomb

Okay, thanks for the color there. And then my follow-up is more office life science related. We were happy to see the good news updates on those two DC. offices on and from a headline basis, there was no strictly office watch list migrations on. We did, however, see that Seattle life science go straight from a risk three to a risk five. So I was hoping you could speak a bit more as to how we should be thinking about the rest of your life science exposure on especially for properties that were potentially originally purposed for a more traditional office use and then pivoted to the Life Science format on like we saw with the Seattle asset. Just hoping you can kind of speak to the rest of the part, the life science portfolio and how we should be thinking about those properties as offices are, as you know, leasable life science on? That's it for me.

Matt Salem

Sure. I'm happy to do that. And a couple of things. I just want to highlight and maybe the best place to address it. We a we have a lot going on in the portfolio this quarter. But if you take a step back and you think about our management team, our posture in the market and from where we're sitting, it feels like we're getting through most of the major issues, right? We've dealt with we've modified loans, we've restructured loans. We're going to go to title on a couple of these assets, these bigger office, therefore, the office portfolio where we felt like we would have issues like we're largely through that.
We've got one more for rated office loan that Patrick highlighted in his comments that we're in negotiations on with the modification and that likely lead to some increase in reserves. But and as we talked about in the past, the rest of the alpha portfolio, we still feel good that we don't see any near term intermediate term migration of that portfolio into higher risk ratings. So we've come a long way and the market come a long way from this time last year, we didn't know where inflation was going to be we didn't know when the Fed was going to stop hiking. In fact, we had like four more cuts for more hikes ahead of us. And now clearly we're in a much different environment and we're debating how many and when interest rate cuts are going to start, the market has changed a lot.
We've worked through our portfolio. I think overall, we feel like we're in a much better position today than than a year ago with all that uncertainty as it relates to Life Science, we break it down into a couple of a couple of different buckets within our own portfolio, but a little less than half of our portfolio is basically construction. So it's purpose-built very well located. So trophy like real estate within the life science sector. We feel very good about that component of the portfolio. For those reasons, we do have some that was more of a conversion conversion from office traditional office to life science. Those have been converted at this point in time. So don't think about those as traditional office. Those are ready for lab leasing, including our Seattle and transaction or property, and a big subset of those are have leasing in place. I think one of the reasons we saw the jump in the risk rating in the Seattle life science deal, just a big.
It's a big business plan, right? There's a big lease up ahead of us there. And when you add that together with the time that takes in the cost of carry in the market. It just gets really expensive for the existing sponsor. So we'll continue to modify or negotiating that with our with our existing sponsor there. We don't know exactly which way that's going to go yet. Obviously we referenced that as a potential REO, but we could get to a modification there as well. We will see how that how that discussion plays out. And that's a little bit how we're thinking about the overall Life's life science portfolio still, by the way, still a sector. We like a lot. We think obviously, it's had a little bit of cyclicality as it relates to the equity markets. But with where we are today and liquidity returning to the sector, I think we still feel very good about the intermediate and long-term prospects of the Life Science business.

Operator

Don Fandetti, Wells Fargo.

Don Fandetti

Can you talk a little bit more about the sort of difference between your expectations for DE and the $0.25 quarterly dividend? And it sounds like you ran some scenarios. Like what would it take to put you at that tougher and that scenario where DE it gets closer to the $0.25?

Matt Salem

It's Matt, again, I'll I can take that question. And I think the two big factors that could drive that lower, particularly have probably obvious, but portfolio performance. So if we saw continued negative migration in the portfolio, nonperforming loans, REO, et cetera, beyond anything that we're seeing today, obviously, we're incorporating our current views on of, for instance, the Boston office for a loan of course, that's incorporated in what we're projecting currently. But if it goes beyond kind of our current expectations that could impact us and the E and bring that number closer down to that dividend level and then just interest rate cuts, right. We can all look at the forward curve. We're running a number of scenarios beyond that. But but if we got into some type of like major cutting some by the Fed that will put pressure on the portfolio as well. But we're trying to look out a fair a fair amount of quarters here to to make sure that we've got some headroom and gives us time right to we want to have patience. We want to protect book value to work out these REO assets. I think it's what our shareholders really want us to do is use our expertise and as part of the bigger KKR ecosystem. And so we are trying to buy a fair amount of time to be able to effectuate those business plans.

Don Fandetti

And then the comments on office are interesting. It sounds like you're not expecting any intermediate term migration risk ratings other than the one four rated. But what kind of gives you that confidence on just given it seems like there's still a lot of stress and the office on plus you have rate caps and other dynamic?

Matt Salem

Yes, I think what gives us the confidence and we've highlighted this on some on other calls is when you look at the three rated loans in the portfolio. They have very long lease terms in place. So over eight years of lease term in place, they've got a very high, a very high debt yield. And we think at a relatively reasonable leverage, equating to a relatively reasonable leverage point. So and then so that's obviously the entire portfolio that's in that three a number of those. We've clearly already modified written off, cut to restructured with our with our sponsors. We've been proactive about about that. And but it really just comes down to the durability of those cash flows that we're seeing and how much debt yield and leverage we think is in that end, we've got I think we've got a good idea of where the office market is. Obviously we've worked through a number of loans within the KRAP. portfolio. We just got refi'd out on a DC office from home. So we know where there's where there's liquidity. And we're using all that to to obviously make those statements around what we see in the rest of the three rented offices.

Operator

Stephen Laws, Raymond James.

Stephen Laws

Thanks. Good morning.
Matt, follow-up on Sarah's question around Seattle. Can you talk a little bit about how that discussion may play out the timing? Is it something we'll hear about next quarter, whether it's modified or REO? Or is that something that lasts longer than that kind of how that process will play out?

Matt Salem

Yes, Stephen, thank you for the question is always hard to handicap the timing around these discussions. I think this one will go faster. So we should be able to get there and hope for sure we'd have an update. We'll certainly we'll have an update, but potentially more of an idea of what the resolution looks like by our by our next call these discussions are we're pretty deep in them right now. So we should be able to give a more fulsome update at that point in time.

Stephen Laws

And then I think multi-list covered so quick one on the Mountain View, California, Patrick, I think you said it's probably a 2Q event. Is that the specific reserve that will run through D. that we should think about the difference in the loan principal balance versus the slide that shows the projected REO? Or is there other things where it's not necessarily exactly that difference that will run through as a realized loss?

Patrick Mattson

No, Stephen, that's a good question, and that's correct, yes, on page 13 of the supplemental where we highlight the REO schedule, we've got the carrying value. So that gives you a good roadmap for what we expect to happen there in the second quarter.

Stephen Laws

Great. Matt, bigger picture. You know what I guess sort of shifting gears, but what are you looking for to go back on offense, right? I know you look at a lot of investment pipeline across the KKR platform. It seems like you feel like you've got a good handle of proactively addressing your concerns and your commentary a second ago, we've seen that you have comfort in your first three rated loans. What do you expect to do some new originations, especially given the repayments in January, our new originations a Q2 event, or is it something that's going to be later this year or is it not until 25, kind of how do you think about turning back to offense, given where you are with your existing portfolio and your current liquidity?

Matt Salem

Yes. Thank you, Stephen. I would say a couple of things, let's step away from care for a second and think about the broader KKR Real Estate Credit business. You will expect to win somewhere in the magnitude of 8 to 10 billion this year away from away from tariffs. So we've got an active lending business across a variety of different kind of risk reward strategies, bank insurance and debt fund capital. We're seeing a very large return and transaction volumes, both acquisitions and refinance. As I mentioned, obviously, the macros cleared up a fair amount and the market's getting and sea legs again and values have come down a lot. So you see equity investors in real estate trying to put money to work. And it's still a very good lending and lending market just given the elevated rates and the lower basis you can lend on today.
So overall, we do like the market environment to invest today. I think from a Kay rep perspective, it really comes back to what we've talked about in the past, which is I'm just seeing a healthy level of repayments in the portfolio. I don't think we want to increase our leverage profile. But right now, there's still uncertainty. And so as we start to get more repayments, I think that's really where we'll we'll look to redeploy.
You're right. We saw a fair amount of repayments this quarter and repayments in sectors that obviously have a little bit less liquidity like office. So if we see that continuing the portfolio, I think that's really where we'll think about turning it back on hard to predict and project when that happens. But it's more of a back half of the year for us.
If I had to guess today, but we'll continue to monitor monitor that.

Stephen Laws

And then one last quick one, if I may add to Dan's question. You talked about a dividend and kind of what what would push you to that level? You mentioned kind of, I believe, aggressive Fed easing just given the impact of floating-rate portfolio, any considerations of buying your own rate floors at some level to take that tail risk off the table.

Matt Salem

I mean, it's something we've it's something we've looked at and over time at different moments in time right now, it doesn't feel like the best use of of capital, but it's something we can continue to continue to watch.

Operator

(Operator Instructions) Jade Rahmani, KBW.

Jade Rahmani

Thank you very much and thanks for all the color in the in the presentation on just a basic question. When we think of interest income, what percentage of the interest that Cara receives is funded out of existing reserves, VERSUS property cash flows and is there, perhaps a third, sorry that I haven't thought and thinking about that.

Matt Salem

Hey, Jade. It's Matt. Thanks for the question today. It's not a number I have in front of me, right now we can take a deeper look and look at that. I mean, if you think about you're most of our largest asset type and the second largest asset type of multifamily and office. And most of those are leased assets or in some high level of occupancy. So I would think that the majority of the portfolio is going to be the income coming up support into the portfolio, I suppose is coming from actual property cash flows. There's obviously some business plans that are in construction or in lease up, and that's really where the reserves are going to factor in the high. The big amount of reserves are going to factor in, but that don't have the exact your number in front of me.

Jade Rahmani

Follow-up would just be, you know what you think the true drivers of default will be in this market. You mentioned in multifamily, you don't expect much pressure. It sounds like there'll be modifications discussions around interest-rate caps, but you don't expect much default there. So what at its core do you think is the driver of default? I know in a lot of cases for the mortgage, much of the interest is in fact, funded out of interest reserves, which is similar to it construction loan.

Matt Salem

Right. So I think come, I guess, a couple of things. Let's just state the obvious big secular change and value change in office. So I think that's despite cash flow in some cases, like, yes, there's clearly a very big deterioration there. So that April will be on its own and we're all seeing that. We know that the other places I think you could see it is just these bigger lease-up plans I think the Seattle life science is a good example of that where you're in the right sector, wherein a good property leasing has slowed down. The business plan is very expensive to implement from our existing sponsor's perspective. And that obviously is creating in issue and discussions with that loan. So you'll see that in other places, I think as well on the multifamily side, I speak from our own portfolio, which again tends to be very high quality real estate. There's a lot of liquidity there, I think, across the board. But certainly you could see some noise in the multifamily sector, especially if you have sponsors and permitting like value by the value, add business plans, heavy renovations that take a long time. And then you're trying to kind of release it because those are, again, they're just deeper, longer time periods that you're really exposed to the cost of capital in the market today. So I'd highlight a few of those things.

Jade Rahmani

Okay. Thanks. And then just going through the our portfolio details, when I look to Life Science specifically and I compare committed principle to current principle I-many loans, there is a substantial difference, which means there's a lot of future fundings, which means these are not leased assets. These are development deals and there is very weak leasing in life science. I know you said long term you're bullish, but how do you think about the outlook for those assets? Are we going to see further nonperformance beyond the Seattle assets.

Matt Salem

We'll set our expectation at this point in time. I think that when we look at those one, they're in very strong locations. We're in on those construction deals. We're in Cambridge with Seaport in Boston, and we're in South San Francisco. So the these are very, very strong locations for life science, the two biggest hubs in United States and their purpose built on. And I think there's going to be a fair amount of demand for that for that high-quality real estate. So it's not our expectation at this point in time, but you're right to highlight that there is a lease up component involved here. It's just the quality of the real estate and the location. We think in our basis, obviously. But we think we'll overcome potential issues there, but there's some uncertainty.

Jade Rahmani

And lastly, just on the Seattle, since that was originated in October of 21, you said it was converted from traditional office to life science. So that probably took some time, but still it's a three year loan and also surprised you I went from a three to a five in just one quarter. What do you think a reasonable time line is to consider stabilizing and optimizing that asset?

Matt Salem

Well, we're doing the work on that now in terms of just really understanding you have to lease up that asset. But it Seattle, in particular, is a little bit smaller life science market. So that one will take it's going to take a little bit of time, but it could it could take anywhere from 18 plus 24 months plus to so I fully stabilized that asset from a leasing perspective.

Operator

Rick Shane, JPMorgan.

Rick Shane

Thanks, guys, for taking my questions this morning, and I apologize we're bouncing around a little bit. So some of this has been covered. I apologize, but can you talk a little bit of doubt on the ability to redeploy capital as you realize losses and are removing loans from nonaccrual and any potential impact on us and I eye going forward.

Patrick Mattson

Sure. I can take that, Matt. I think in the prepared remarks, we tried to give some context around this. I think the timing component is the difficult one, right? We want to make sure that we really optimize the value of the REO portfolio and that and that's really the way we're thinking about it. Is, and that's the portion of the portfolio that is not creating earnings. There's actually a drag around that from OpEx and some financing we have against those those assets as we stated on the on on this in the script, if you just repatriate our basis in those assets, we think that could generate an additional $0.12 of DE per quarter another question is how much time it takes to get there. And that goes back to our comment where we're going to have to be patient a little bit to Jade's last remark. Some of these will take a little bit of time to get through them. But as we sell those assets stabilize and sell them in the market, we should be able to. And of course, it can happen at different times for each asset. We should be able to repatriate that equity and then invested in new loans and start to get some of that $0.12 back the $0.12 per quarter is based again on our basis, not on where we hope and the goal is to sell these assets. Obviously, we think we're going to make more over time as why we're going to implement this business plan. So just gives you a little bit of context of where we could go. But if not we're not thinking about this as like in the next quarter or two like we're trying to make sure that we have the runway to to be patient.

Operator

Kelly Wang, Citi.

Kelly Wang

Thank you. Are maybe you could talk about as you look at the new deal opportunities coming to the market today?And how are the spreads trending and what are you seeing from the competitive front?

Matt Salem

Yes, thank you for the question. It's Matt again, I'll take that again. I'll speak a little bit to our broader the broader real estate credit platform here at KKR, where we're we're actively lending in the market on a daily on a daily basis. I would say we again, we have seen a pretty big return in transaction volumes, both acquisition and refinance needs. Our pipeline right now across all of our different pockets of capital is up over 50% from last year and still down from, call it the peak 21 type of levels, but it has picked up a lot over the course of the last call it couple of months as you saw the Fed pivot and where we're seeing the most competition, I would say is on real stabilized assets and the insurance capital and the agencies, Freddie Mac and Fannie Mae. So that's really where you've seen the most aggressive from a spread perspective from a from a spread of yield. As you look at what's going on with investment grade corporates, you look at what's going on with CMBS spread tightening happening across most of fixed income. And that's happening in the loan market as well. So it's like stabilized lending. What used to be low two hundreds type of spread is now gravitating into the one hundreds that we've seen insurance companies go as tight as 100, 50 basis points over at this point. So it is there's clearly a lot of demand for lending in today's market. I think the big question as we all know is the banking market. They are roughly 40% of the overall commercial real estate lending market. We've seen on a little bit more bank activity, but it's still largely on the sidelines. And as we start to pickup volumes this year, that's the big question is, will there be a gap in the need for financing? Of course, there'll be some alternative lenders like ourselves that can step in and fill that gap on. But I think that that that will this year will figure out a little bit of how much the banking system is really going to come back online. One good news for PRS. I'd say is that what we are seeing from, especially the larger banks willingness to lend on loan on loan facilities and warehouse facilities much more. There's been a little bit of a shift away from direct lending mortgage origination into more facility type of loan of lending. It's better capital, it's safer. And so that will be in my mind, one of the big <unk> changes as we come out of this market environment as the banks reduced their footprint and the direct mortgage origination business likely increase their footprint in the US on the loan and loan warehouse side of things.

Operator

And ladies and gentlemen, this concludes our question and answer session. I would like to turn the conference back over to Jack Switala for any closing remarks.

Jack Switala

Thanks, operator, and thanks, everyone, for joining today as you reach out to me or the team here if you have any questions. Thanks and take care.

Operator

The conference has now concluded. Thank you for attending today's presentation. You may now disconnect.M